---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-26-006848"
form_type: "8-K"
ticker: "VBIO"
cik: "0001787740"
company_name: "Valion Bio, Inc."
filed_at: "2026-09-01T10:00:22+00:00"
generated_at: "2026-09-01T10:10:40.478418+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Valion Bio appoints Lisa Wolf President/COO, adds two directors, raises $7.7M from 3i

## Summary
- Lisa Wolf becomes President and COO, retains CFO role; former CEO Michael K. Handley has departed.
- Jared Malbin (Lucid Capital Markets COO) and Thomas Jensen (Allarity Therapeutics CEO) joined the board.
- Letter agreement with 3i: issued 100 Series B and 7,637 Series C preferred plus warrants for $7.737M; $1.5M cash to company.
- Warrants cover 1,053,969 shares at $3.62 exercise; $6.137M retained by 3i to satisfy overdue cash true-up.
- Lead asset Entolimod targets projected $7.8B Acute Radiation Syndrome market by 2032.

## SEC filing metadata
- accession: 0001683168-26-006848
- form_type: 8-K
- ticker: VBIO
- cik: 0001787740
- company_name: Valion Bio, Inc.
- filed_at: 2026-09-01T10:00:22+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/0001683168-26-006848-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/valion_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-26-006848
- JSON: https://secwatch.observer/filing/0001683168-26-006848.json
- Plain text: https://secwatch.observer/filing/0001683168-26-006848.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.